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Abstract
Background: PUFAs are important molecules for membrane order and function; they can modify inflammation-
inducible cytokines production, eicosanoid production, plasma triacylglycerol synthesis and gene expression. Recent
studies suggest that n-3 PUFAs can be cancer chemopreventive, chemosuppressive and auxiliary agents for cancer
therapy. N-3 PUFAs could alter cancer growth influencing cell replication, cell cycle, and cell death. The question
that remains to be answered is how n-3 PUFAs can affect so many physiological processes. We hypothesize that
n-3 PUFAs alter membrane stability, modifying cellular signalling in breast cancer cells.
Methods: Two lines of human breast cancer cells characterized by different expression of ER and EGFR receptors
were treated with AA, EPA or DHA. We have used the MTT viability test and expression of apoptotic markers to
evaluate the effect of PUFAs on cancer growth. Phospholipids were analysed by HPLC/GC, to assess n-3
incorporation into the cell membrane.
Results: We have observed that EPA and DHA induce cell apoptosis, a reduction of cell viability and the
expression of Bcl2 and procaspase-8. Moreover, DHA slightly reduces the concentration of EGFR but EPA has no
effect. Both EPA and DHA reduce the activation of EGFR.
N-3 fatty acids are partially metabolized in both cell lines; AA is integrated without being further metabolized. We
have analysed the fatty acid pattern in membrane phospholipids where they are incorporated with different
degrees of specificity. N-3 PUFAs influence the n-6 content and vice versa.
Conclusions: Our results indicate that n-3 PUFA feeding might induce modifications of breast cancer membrane
structure that increases the degree of fatty acid unsaturation. This paper underlines the importance of nutritional
factors on health maintenance and on disease prevention.
Background
Breast cancer is the most common cancer among women
worldwide, with an estimated 1.4 million new breast can-
cer cases only in 2008. Epidemiologic and experimental
studies suggest that dietary fatty acids influence the
development and subsequent progression of breast can-
cer [1-3]. The role that long-chain n-3 polyunsaturated
fatty acids (PUFAs), eicosapentaenoic acid (EPA, 20:5n-3)
and docosahexaenoic acid (DHA, 22:6n-3), play in the
aetiology of cancer has been highlighted by animal
experiments and in vitro studies [4,5]. A number of
mechanisms have been proposed for the anticancer
actions of n-3 PUFAs. The most prominent mechanism
for the chemopreventive action of n-3 PUFAs is their
suppressive effect on the production of arachidonic acid
(AA)-derived prostanoids, particularly prostaglandin E2
(PGE2), which has been implicated in the immune
response to inflammation, cell proliferation, differentia-
tion, apoptosis, angiogenesis and metastasis [6].
The n-3 PUFAs might alter the growth of tumour cells
by influencing cell replication, by interfering with compo-
nents of the cell cycle or by increasing cell death either by
way of necrosis or apoptosis [7,8]. For example, these fatty
acids are involved in regulating the tumour p53 proapop-
totic signal and superoxide dismutase (SOD) levels, telo-
mere shorting and tumour angiogenesis [9]. In vitro
treatment with DHA arrested cell-cycle progression in
human-derived breast cancer and malignant melanoma
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is reported to arrest the growth of K-562 human leukemic
and many other cancer cells accompanied by down-
regulation of cyclin expression in some instances [12-14].
In addition, recent studies of human breast cancer
have shown that n-3 PUFAs up-regulate syndecan 1
(SDC-1), which has been shown to play a role in cell
adhesion [15,16], inhibit matrix metalloproteinases [17]
and decrease invasion of tumour cells. SDC-1 induces
apoptosis in myeloma cells and some studies suggest a
similar property in breast cancer cells [18,19]. The tran-
scriptional pathway for the n-3 PUFA regulation of
SDC-1 expression involves the nuclear hormone recep-
tor peroxisome proliferator-activated receptor gamma
(PPARg) [20]. Moreover n-3 PUFAs down-regulate the
expression of HER2/neu, a well characterized oncogene
that plays a key role in aetiology, progression and che-
mosensitivity of various types of human cancer in which
this oncogene is over-expressed. HER2/neu encodes
transmembrane tyrosine kinase orphan receptor
p185
Her2/neu, which regulates biological functions includ-
ing cellular proliferation, differentiation, motility and
apoptosis [21].
Nevertheless the mechanism by which n-3 PUFAs
inhibit the growth of breast cancer cells is not well
understood, but it has been suggested that these fatty
acids might change the fluidity and structure of the cell
membrane. In fact, changes in the structural characteris-
tics of the plasma membrane in mammalian cells can
modify the activity of proteins that function as ion chan-
nels, transporters, receptors, signal transducers or
enzymes [21-25].
In this study, we have investigated the impact of EPA,
DHA and AA on breast cancer cell growth, on cell sig-
nalling in apoptosis and on epidermal growth factor
receptor (EGFR) activity. We hypothesize that the
alteration of cellular cycle, of gene expression and the
induction of apoptosis determined from n-3 PUFAs are
also a consequence of membrane architecture modifica-
tions. For these reasons we have analyzed PUFA incor-
poration in breast cancer membrane and their PL-
specific enrichment.
Methods
Cell lines and culture conditions
Human breast cancer cell lines MDA-MB-231 (ER-nega-
tive) and MCF-7 (ER-positive) were kindly provided by
Dr P. Degan from the IST (Italian National Cancer
Research Institute, Genoa Italy, Laboratory of Molecular
Mutagenesis and DNA Repair). Both cell lines are
derived from human mammary adenocarcinoma; the
MCF7 line retains several characteristics of differen-
tiated mammary epithelium, including the ability to
process estradiol via cytoplasmic estrogen receptors.
The MDA-MB-231 cells over-express EGFR.
These cell lines were maintained in DMEM (Gibco-
BRL, Life Tecnologies Italia srl, Italy) supplemented
with 10% fetal bovine serum (FBS), 100 U/ml penicillin,
100 mg/ml streptomycin and 2 mM glutamine.
Medium for treatments (MFT) was DMEM supple-
mented with 10% FBS. Cells were grown at 37°C in a
5% CO2 atmosphere with 98% relative humidity.
PUFAs
EPA (cis-5,8,11,14,17-eicosapentaenoic acid sodium salt),
DHA (cis-4,7,10,13,16,19-docosahexaenoic acid sodium
salt) and AA (arachidonic acid sodium salt) were pur-
chased from Sigma-Aldrich, USA. The PUFAs were dis-
solved in ethanol and stored at -80°C under nitrogen gas.
Antibodies
The mouse monoclonal anti-Bcl2 antibody (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) and the C20
goat polyclonal anti-procaspase-8 p18 antibody were used
to study the n-3 PUFA induction of the apoptosis process.
The 1005 rabbit polyclonal anti-EGFR antibody and the
11C2 mouse monoclonal anti-pEGFR antibody (Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) were used
to investigate the alterations of EGFR receptors after treat-
ment with PUFAs. The monoclonal anti-actin (AC-40)
antibody (Sigma-Aldrich, USA) was used to normalize gel
loading.
Bound primary antibodies were visualized by second-
ary horseradish peroxidase (HRP)-linked antibodies
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
and immunoreactivity was assessed by chemilumines-
cence (ECL, Amersham).
Cell viability assay
The numbers of viable cells exposed to fatty acids were
evaluated by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) colorimetric assay [26].
Initially, cells were seeded and cultured in 96-well plates
for 48 h to allow adhesion to the plate and to reach 50-
60% confluence. After this period, the culture medium
was changed to the experimental medium supplemented
with EPA or DHA or AA then cultured for 72 h. We stu-
died the effects of different concentrations of PUFAs
(50-300 μM). The final concentration of ethanol (<1%) in
the culture medium had no antiproliferative effect on any
cell line tested; therefore, 10 μl of MTT stock solution
(5 mg/ml in PBS, pH 7.5) was added to each well and
incubated for 4 h as a control. Then 100 μl of solubilizing
solution (10% SDS in 0.01M HCl) was added and incu-
bated overnight. Plates were read at 540 nm in a plate
reader. All reagents were purchased from Sigma-Aldrich,
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the results are expressed as relative growth rate (RGR) in
comparison to controls that were exposed to a concen-
tration of ethanol equal to that in the samples exposed to
fatty acids.
Cell treatment
Cell culture experiments were done with the MDA-MB-
231 and MCF-7 cell lines to determine the concentra-
tions of EPA (230 μM), DHA (200 μM), required to
inhibit growth by 20-30%, and AA (200 μM). Cells were
seeded at 1.5 × 10
4 cells/cm
2 for MDA-MB-231 and at
3×1 0
4 cells/cm
2 for MCF-7 in 18 ml of medium con-
taining 10% FBS and allowed to adhere for 48 h, then
the medium was replaced with 18 ml of fresh medium
(DMEM, 10% FBS) containing the experimental fatty
acids and incubated for 72 h without changing the med-
ium. Experiments included untreated cells that were not
exposed to any exogenous fatty acids but to an equal
content of ethanol during the incubation to serve as
controls. After 72 h, cells were harvested using trypsin-
EDTA and centrifuged at 900 rpm for 10 min. The
supernatant was removed and the pellets were subjected
to lipid analysis.
For western blot analysis, cells were harvested by scrap-
ing in phosphate-buffered saline containing 0.4 mM
Na3VO4. Cells were centrifuged and then suspended in
1.4 ml of lysis buffer (1% Triton X-100, 10 mM Tris buf-
fer, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4,
1 mM phenylmethylsulfonyl fluoride, 75 mU/ml aproti-
nin), kept on ice for 20 min and then disrupted by
10 strokes in a tight-fitting Dounce homogenizer. The
cell lysate was centrifuged (5 min at 1300 g)a n dt h e
supernatant was transferred to an eppendorf tube. Total
protein was determined by the Lowry assay [27].
Lipid composition analysis
Cell lipids were extracted with three different chloro-
form/methanol mixtures (1:1, 1:2 and 2:1, v/v) and parti-
tioned with a theoretical upper phase (chloroform/
methanol/water, 47:48:1, by vol.) and then with water.
The organic phase was dried and then suspended in
chloroform/methanol (2:1, v/v) for the analysis of total
and PL fatty acids.
Purification of single PL moieties was achieved with
an HPLC-ELSD system (Jasco, Japan) equipped with one
pump, a SCL-10 Advp, a degasser module and a Rheo-
dyne manual injector with 20 μl sample loop and a col-
umn (length 250 mm, I.D 4.6 mm and film thickness
5 μm) packed with silica normal-phase LiChrospher Si
60 (LiChroCART 250-4, Merck, Darmstadt, Germany).
The chromatographic separation was achieved with a
linear binary gradient of 0% B to 100% B in 14 min and
then 100% B for 9 min. The total chromatographic run
time was 40 min/sample; 23 min analysis, 12 min to
restore initial conditions and 5 min for re-equilibration.
Eluent A was chloroform/methanol/water (80:19.5:0.5,
by vol.) and eluent B was chloroform/methanol/water
(60:34:6, by vol.) and the flow rate of the eluent was
1.0 ml/min. An evaporative light-scattering detector
(ELSD) was used to detect and quantify the separated
PL species.
After elution, the eluate was split with one part going
to the detector and nine parts to a Gilson fraction col-
lector model 201 to collect the different PL classes for
GC analysis.
Total fatty acids and PL fatty acids were determined as
methylesters by gas chromatography (GC). The methyl
esters were obtained by reaction with 3.33% (w/v) sodium
methoxide in methanol and injected into an Agilent
Technologies (6850 series II) gas chromatograph
equipped with a flame ionization detector (FID) and a
capillary column (AT Silar) (length 30 m, film thickness
0.25 μm). The carrier gas was helium, the injector tem-
perature was 250°C, the detector temperature was 275°C,
the oven temperature was set at 50°C for 20 min and
then increased to 200°C at 10°C min
-1 for 20 min.
Western blot analysis for Bcl2, caspase-8, EGFR and
pEGFR
Control and treated cell lysates (100 μg protein/lane)
were separated by SDS-PAGE (10% polyacrylamide gel),
transferred to a polyvinylidene difluoride (PVDF) mem-
brane and analysed by western blot with anti-Bcl2
(1:100), anti-caspase-8 (1:500) and b-actin (1:1800) anti-
bodies. The PVDF membrane was blocked for 1 h in
blocking buffer 5% (w/v) dried non-fat milk in Tris-buf-
fered saline (T-TBS: 10 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 0.1% (v/v) Tween
®20) followed by incubation
with an appropriate primary antibody in blocking buffer
at room temperature for 2 h. The blots were washed
with T-TBS and then incubated with the proper second-
ary antibody in blocking buffer at room temperature for
1 h. The protein bands were visualized using ECL wes-
tern blot detection reagents (PerkinElmer, USA).
For the analysis of EGFR and p-EGFR, cells treated or
not with DHA and EPA were cultured in MFTs supple-
mented with 10 nM EGF (Sigma-Aldrich, St. Louis, MO,
USA) and incubated at 37°C for 15 min of stimulation.
Cells were washed twice with ice-cold phosphate-buffered
saline (PBS) and lysed as described above. Equal amounts
of protein (100 μg/lane) from each treatment were sepa-
rated by SDS-PAGE (10% polyacrylamide gel) and trans-
ferred onto a PVDF membrane then blocked in blocking
buffer at room temperature for 1 h. Primary antibodies to
EGFR and p-EGFR were diluted 1:200 in blocking buffer
at room temperature for 2 h and then with an appropriate
secondary antibody at room temperature for 1 h. Parallel
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antibody b-actin diluted 1:1800 to confirm equal protein
loading.
The relative intensities of band signals were deter-
mined by digital scanning densitometry and b-Actin was
used to normalize the results to protein content.
Statistical analysis
The data are presented as mean ± SD. Student’s
unpaired t-test was used for comparisons between trea-
ted and control cells and the level of statistical signifi-
cance was set at P < 0.05 and P < 0.01.
Results
The effects of treatment with PUFAs on breast cancer cell
growth
To evaluate the effects of PUFAs on breast cancer pro-
liferation, cells were incubated for 3 days in medium
supplemented with n-3 and n-6 PUFAs (EPA, DHA and
AA).
The effect on cell viability of MDA-MB-231 and
MCF7 cells was assessed and quantified by the MTT
assay. As shown in Figure 1, cells were treated with var-
ious concentrations of n-3 and n-6 PUFAs in the range
50-300 μM.
DHA and EPA induce a dose-dependent reduction of
cell viability at concentrations > 200 μM (Figure 1A and
1B).
In contrast, AA (Figure 1C), the major n-6 PUFA, had
no significant effect on MCF7 cell viability. The MCF7
cell line was more resistant than the MDA-MB-231 cell
line to all treatments with PUFAs.
From these experiments, we extrapolated the dose to
be used in successive experiments to assess n-3 PUFA
incorporation into cell membrane PLs: 230 μM for EPA,
200 μM for DHA, which correspond to 70~80% viability
for both cell lines, and 200 μM for AA.
DHA and EPA induce apoptosis in breast cancer cells
In order to delineate the possible mechanism(s) by
which EPA and DHA induce apoptosis we examined the
cytoplasmic levels of the Bcl2 protein. Figure 2A and 2B
indicate that there was a slight reduction of Bcl2 level in
MCF7 cells after treatment with 200 μMD H A ,w h e r e a s
treatment with 230 μM EPA determined the loss of sig-
nal; the expression of Bcl2 is also decreased when
MDA-MB-231 cells are treated with 230 μME P Aa n d
the protein is not detectable after incubation with
200 μM DHA.
Furthermore, apoptosis involves the activation of pro-
caspase-8 (55 kDa) by its cleavage to caspase-8 (18
kDa); this smaller protein together with caspase-3 med-
iates the rapid dismantling of cellular organelles and
architecture [28].
The expression of procaspase-8 was determined by
western blot analysis. In Figure 3A and 3B it is possible
to observe a reduction of the proform of caspase-8 for
both cell lines treated with EPA and DHA; the reduc-
tion was statistically significant after DHA treatment in
both cell lines, and also after EPA treatment of MCF7
cells.
EPA and DHA alter the EGFR and pEGFR levels in MDA-
MB-231 cells
EGFR is usually activated in response to extracellular
ligands (EGF) by its phosphorylation; ligand binding
leads to homo- or heterodimerization with another
ligand-bound ErbB receptor, and transmits extracellular
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Figure 1 Effects of PUFA on viability of breast cancer cells. The
effect on cell viability of PUFA in MDA-MB-231 and MCF7 cells is
assessed and quantified by MTT assay. Cells are treated with various
concentrations of EPA (A), DHA (B), and AA (C). Cells are seeded and
cultured for 48 h in a 96-well plate, after this period, the medium is
replaced with fresh medium for treatments with AA, EPA, or DHA
and incubated for further 72 h. The numbers of viable cell exposed
to fatty acids are evaluated by a colorimetric 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Data represent
the mean of eight values and results are expressed as Relative
Growth Rate (RGR) in comparison with controls (100%). * p < 0.05;
** p < 0.01 compared to control cells.
Corsetto et al. Lipids in Health and Disease 2011, 10:73
http://www.lipidworld.com/content/10/1/73
Page 4 of 16mitogenic signals to downstream target signalling cas-
cades that involve cell survival and proliferation, such as
phosphatidylinositol 3-kinase (PI3K)/Akt, mitogen-acti-
vated protein kinase (MAPK) and signal transducer and
activator of transcription 3 (STAT3) [29].
In human breast cancer cell lines, such as MDA-MB-
231, the EGFR level is elevated compared with that in
other breast cancer cells, such as MCF7 [30]; for this
reason, we have studied the effects of DHA and EPA on
EGFR activity mainly in MDA-MB-231 cells.
Figure 4 reports the effects of EPA and DHA treat-
ments on expression and activation of EGFR in presence
of EGF. EPA did not modify EGFR expression in breast
cancer cells; while EGF stimulation significantly increase
EGFR phosphorylation to about 140%; co-treatment
with EPA/EGF significantly inhibit EGFR activation
down to about 40% compared to control non stimulated
cells (Figure 4A).
As shown in Figure 4B, DHA significantly reduces the
EGFR level (70%) compared to control cells and com-
pletely inhibit EGFR activation in cells treated with
DHA or DHA/EGF.
Total fatty acid profile after treatment with PUFA
Treatment with AA, EPA or DHA alters the FA profile
in MDA-MB-231 and MCF7 cells compared with con-
trol cells (Table 1).
Treatment of both cell lines with AA resulted in a sig-
nificant increase of AA content in total cell lipids, from
14.40% to 46.85% in MDA-MB-231 and from 12.73% to
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0
20
40
60
80
100
120
EPA DHA
CTR
TREATMENT
 
Bcl2 MDA-MB-231
0
20
40
60
80
100
120
EPA DHA
CTR
TREATMENT
A                 MCF7
Bcl2
ȕ-actin 
B             MDA-MB-231 
CTR        EPA      CTR      DHA
Bcl2 
ȕ-actin
CTR        EPA      CTR       DHA      
Figure 2 Effects of n-3 PUFA on Bcl2 expression. Both cell lines
were treated with DHA (200 μM) or EPA (230 μM) for 72 h. Control
and treated cell lysates are separated on 10% SDS-PAGE and
transferred to PVDF membrane. The expression of the anti-apoptotic
protein Bcl2 was assessed by western blot and semi-quantitative
analysis performed by plate scanning. b actin was used to normalize
results of protein content. A: MCF7 cells, B MDA-MB-231 cells.
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Figure 3 Effects of n-3 PUFAs on caspase-8 expression.T h e
determination of the integrity of the procaspase-8 after treatment
with DHA (200 μM) and EPA (230 μM) for 72 h was assessed in
both cell lines. A: MCF7 cells treated with DHA (200 μM) or EPA
(230 μM) for 72 h. B: MDA-MB-231 cells treated with DHA (200 μM)
or EPA (230 μM) for 72 h. Semi-quantitative analysis performed by
plate scanning. b-actin was used to normalize results of protein
content. ** p < 0.01 compared to control cells; n = 3
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treated with 230 μM EPA for 72 h, lane 1 control, lane 2 230 μM EPA, lane 3 EGF, lane 4 EGF+EPA. B: MDA-MB-231 treated with 200 μM DHA
for 72 h, lane 1 control, lane 2 200 μM DHA, lane 3 EGF, lane 4 EGF+DHA. The relative intensities of band signals, reported in graphics, are
determined by digital scanning densitometry. b-actin was used to normalize results of protein content. * p < 0.05; ** p < 0.01 compared to
control cells; n = 3.
Table 1 Total fatty acid composition of PUFA-treated breast cancer cells
MDA-MB-231 MCF-7
CTR AA EPA DHA CTR AA EPA DHA
C:16:0 13.91 ± 2.19 13.48 ± 2.91 6.57 ± 0.91** 8.66 ± 1.25** 16.03 ± 4.06 15.52 ± 1.56 14.7 ± 1.76** 11.14 ± 3.59
C 16:1 1.61 ± 0.85 1.19 ± 0.87 0.87 ± 0.58** 0.77 ± 0.42* 8.25 ± 3.27 2.97 ± 0.86** 3.95 ± 0.54** 2.94 ± 1.53**
C 18:0 17.57 ± 1.97 10.46 ± 2.05* 5.15 ± 1.03** 6.39 ± 1.30** 14.83 ± 1.58 15.73 ± 1.76 10.41 ± 2.49** 9.46 ± 0.89**
C 18:1 26.14 ± 4.74 15.91 ± 4.21* 8.15 ± 0.95** 9.65 ± 1.29** 30.14 ± 2.91 12.12 ± 1.19** 12.21 ± 1.94** 9.77 ± 1.12**
C 18:2 6.05 ± 2.38 3.07 ± 0.65** 2.38 ± 0.17** 2.46 ± 0.32** 4.23 ± 0.73 2.48 ± 1.27** 2.26 ± 0.42** 1.66 ± 0.21**
C 18:3 1.54 ± 4.10 0.68 ± 0.37 0.22 ± 0.16 0.32 ± 0.10** 1.32 ± 0.87 0.96 ± 0.53* 0.59 ± 0.36* 0.63 ± 0.61*
C 20:3 1.64 ± 0.21 1.60 ± 0.10 0.72 ± 0.37** 1.18 ± 0.70* 2.41 ± 0.67 1.28 ± 0.11** 0.67 ± 0.09** 0.78 ± 0.16**
C 20:4 (AA) 14.40 ± 2.92 46.85 ± 10.48* 2.56 ± 0.87** 3.91 ± 0.50** 12.73 ± 2.90 44.26 ± 3.80** 3.13 ± 0.57** 3.20 ± 0.55**
C 20:5 (EPA) 2.42 ± 0.70 0.70 ± 0.23** 38.75 ± 3.52** 1.98 ± 0.43 3.22 ± 0.98 0.74 ± 0.75** 34.16 ± 3.89** 4.90 ± 0.51**
C 22:5 (DPA) 7.04 ± 1.10 3.61 ± 0.44** 33.30 ± 1.83** 2.94 ± 0.62** 1.10 ± 0.71 1.29 ± 0.45 15.80 ± 3.32** 0.96 ± 0.14
C 22:6 (DHA) 7.68 ± 1.55 2.45 ± 0.60** 1.29 ± 0.35** 61.76 ± 3.93** 5.73 ± 2.36 2.65 ± 0.68** 2.12 ± 0.31** 54.55 ± 6.02**
SFA 33.35 ± 5.50 23.94 ± 4.88* 11.76 ± 1.90** 15.05 ± 2.52** 30.86 ± 3.21 31.24 ± 2.89 25.11 ± 3.81** 20.60 ± 4.18**
MUFA 27.74 ± 4.69 17.10 ± 4.61* 9.01 ± 0.82** 10.41 ± 1.06** 38.39 ± 4.36 15.09 ± 1.62** 16.16 ± 2.02** 12.71 ± 2.27**
n-3 PUFA 18.68 ± 3.93 7.44 ± 0.56** 73.56 ± 3.16** 67.00 ± 3.45** 11.37 ± 3.71 5.63 ± 1.58** 52.67 ± 6.24** 61.05 ± 5.96**
n-6 PUFA 22.09 ± 3.15 51.52 ± 9.81** 5.67 ± 1.37** 7.55 ± 0.70** 19.38 ± 3.58 48.03 ± 4.00** 6.06 ± 0.76** 5.64 ± 0.59**
Breast cancer cells were treated with solvent (ethanol) as control, AA (20:4, n-6), EPA (20:5, n-3), and DHA(22:6, n-3).
Fatty acid composition was analyzed and expressed as percentage of total fatty acids (mean ± SD).
Asterisks indicate the significant differences between treated- and control cells (n=10, *P < 0.05; **P < 0.01).
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231 show a significant decrease of EPA, docosapentae-
noic acid (DPA) and DHA, whereas the data for MCF7
cells show a significant reduction of only EPA and DHA.
When both cell lines were treated with EPA, the con-
tent of this FA in total cell lipids was increased signifi-
cantly and we observed a significant reduction of AA.
Unexpectedly, we found an increase of DPA content,
indicating that EPA is incorporated into cells and is
further metabolized by elongation.
The treatment with DHA determines a significant
increase of DHA content in both cell lines and an
increase of EPA content in MCF7, probably due to a
retro conversion; a significant reduction of AA content
was also measured.
Effects of treatment with PUFAs on PL composition in
breast cancer cells
Table 2 and 3 give the fatty acid composition of specific
PLs in MDA-MB-231 and MCF7 cells treated with n-3
or n-6 PUFAs; to simplify the tables SD, are reported as
plain numbers above the bold mean value.
After treatment with AA, the content of this n-6
PUFA was increased significantly in PE and PC in
MDA-MB-231 (Figure 5, Table 2). The treatment
induced a reduction of omega-3 PUFAs, particularly
EPA, that was significantly decreased in all phospholi-
pids but SM; while DHA content was decreased after
AA treatment only in PE and PC, the other two omega-
3 fatty acids namely DPA and ALA (C18:3) were
decreased in all phospholipids but SM.
Incubation with EPA caused an increase of EPA con-
tent in all PLs in MDA-MB-231 cells. In particular, the
incorporation of EPA was different in relation to the PL
moiety with highest levels of incorporation in PI and
PC. There was a decrease of monounsaturated FA in PE
and PC, and a significant increase of polyunsaturated
FA in PI and PC. Furthermore, an increase of DPA con-
tent was found in all PLs, especially PC. The content of
AA was significantly decreased in all phospholipids but
SM.
After treatment of MDA-MB-231 cells with DHA, the
content of this fatty acid was significantly increased in
all cell membrane PLs, but not in SM.
We measured a significant decrease of the content of
EPA in PE, PS, PI and PC. The concentration of AA
was significantly reduced in PE and PI and SM as the
result of treatment with DHA.
In MCF7 cells (Figure 6, Table 3), the treatment with
AA induced a significant increase of this fatty acid in all
PLs, except in SM; a significant reduction of EPA and of
DHA in PE, PI, PS and PC was also measured.
After treatment with EPA, the EPA and DPA content
was significantly increased, especially in PE, PI, PS and
PC. The concentration of DHA was significantly
decreased in PE and PI, whereas the AA content was
significantly reduced in PE, and PI.
The exposure of MCF7 cells to DHA determined a
significant increase of DHA in all PLs, but not in SM,
and of EPA content in PE, PI, and PC, whereas the con-
tent of AA was significantly reduced only in PE, PI and
PS.
Also in these cells a significant decrease of monounsa-
turated fatty acids is always present when the cells are
treated with n-6 and n-3 PUFAs; while saturated fatty
acids are in most cases constant.
Moreover also 18:2, 18:3 (n-3) and 20:3 (n-6) are sig-
nificantly decrease after PUFA treatment.
As far as phospholipids content concerns, it is worth
noting the significant decrease of SM content (from
11.32% to 9.02%, data not shown) in MCF7 after treat-
ment with DHA even if, sphingomyelin is the phospholi-
pid less influenced in its fatty acid composition by
PUFA treatment. The other treatments did not modify
the distribution of PL in both cell lines.
Discussion
Breast cancer is the leading cause of the death among
women in the world. The principal effective endocrine
therapy for treatment on this type of cancer is anti-
estrogens, but therapeutic choices are limited for estro-
gen receptor (ER) negative tumor, which are more
aggressive. Moreover the development of ER positive
cancer cells that are resistant to chemotherapeutic
agents is a major factor responsible to the successful
treatment of breast cancer. This is a strong input to dis-
cover new approaches in vitro.
Several epidemiologic and clinical studies have shown
that n-3 PUFAs are able to provide beneficial effects in
a wide variety of pathologies ranging from autoimmune
and inflammatory diseases to neurological and psychia-
tric disorders and, in particular, to several types of
malignancy, including ovarian, pancreatic, prostate,
renal, colorectal and breast cancer [31-33].
This study was prompted by the observation that
MDA-MB-231 and MCF7 breast cancer cell lines showed
a significant reduction in cell number following treat-
ment with n-3 PUFAs. The same conclusion is not possi-
ble for the AA incubation. We hypothesize that this
reduction in cell number results from both proliferation
reduction and induction of apoptosis. Apoptosis is a
genetically controlled form of cell death that is conserved
from worms to humans. Deregulation of apoptosis is a
hallmark of all cancer cells and the agents that activate
apoptosis in cancer cells could be considered as anti-
cancer therapeutics [34]. In some mammalian cells,
apoptosis can be triggered by members of the Fas/TNF
receptor family. When activated by receptor aggregation,
Corsetto et al. Lipids in Health and Disease 2011, 10:73
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Page 7 of 16Table 2 Phospholipids fatty acid composition of PUFA-treated MDA-MB-231
C16:0 C16:1 C18:0 C18:1 C18:2 C18:3 C20:3 C20:4 C20:5 C22:5 C22:6 SFA MUFA PUFA n-6 PUFA n-3 PUFA Omega-6/Omega-3 AA/EPA AA/DHA
PE CTR 5.13 0.80 19.58 18.11 3.12 0.62 1.58 30.38 3.65 6.14 7.85 24.71 18.90 53.34 35.08 18.26 1.95 8.96 3.93
s.d. 1.87 0.59 2.40 2.59 0.97 0.19 0.37 4.39 0.90 1.01 1.06 3.16 2.80 4.03 3.42 2.01 0.30 2.99 0.79
PE AA 6.16 1.29 22.60* 15.64* 1.52* 0.30* 1.15* 40.72* 0.66* 3.75* 3.09* 28.76* 16.93* 51.08* 43.39* 7.70* 5.69* 81.49* 13.38*
s.d. 0.86 1.12 0.88 0.84 0.14 0.03 0.35 1.29 0.49 0.74 0.45 1.73 0.52 0.89 1.16 0.80 0.61 37.02 1.79
PE EPA 5.64 0.55 20.44 13.68* 1.66* 0.33* 0.84* 8.13* 22.52* 18.86* 1.62* 26.09 14.23* 53.96 10.63* 43.34* 0.25* 0.36* 5.10
s.d. 1.35 0.24 5.47 0.92 0.35 0.07 0.28 1.21 1.33 2.80 0.26 5.28 1.07 3.47 1.13 3.78 0.04 0.07 1.14
PE DHA 6.44 1.14 19.87 8.80* 1.34* 0.27* 0.84* 12.15* 2.10* 2.26* 42.31* 26.31 10.57* 56.55 13.46* 47.24* 0.26* 6.41 0.25*
s.d. 1.86 0.64 3.99 0.62 0.46 0.09 0.45 2.73 0.71 0.45 3.04 5.38 1.95 7.81 3.21 2.96 0.01 3.60 0.02
PI CTR 4.32 1.31 34.32 14.48 2.50 0.50 2.88 25.54 1.44 4.65 3.98 40.05 14.35 41.67 30.34 11.33 3.23 22.84 8.98
s.d. 1.73 1.31 5.38 4.35 1.74 0.35 0.66 3.93 0.65 1.12 1.74 5.37 5.32 5.09 6.33 3.34 1.68 11.79 9.39
PI AA 8.23* 2.40 33.71 13.31 1.44* 0.29* 0.65* 30.03* 0.40* 2.16* 2.94 41.95 15.26 37.99 32.11 5.87* 5.51* 75.95* 10.23
s.d. 2.67 1.24 2.05 1.54 0.40 0.08 0.30 2.86 0.04 0.15 0.36 3.09 2.39 2.53 2.70 0.40 0.69 15.180 1.75
PI EPA 6.16* 1.12 24.38 14.81 2.34 0.47 1.15* 11.53* 14.30* 16.40* 1.32* 30.55* 15.93 48.87* 15.02* 33.85* 0.45* 0.84* 10.35
s.d. 1.23 0.50 2.72 6.18 1.19 0.24 0.48 3.47 5.28 4.92 0.74 2.27 6.31 6.89 2.60 5.10 0.07 0.15 6.91
PI DHA 10.09* 2.99 32.88 10.90 1.96 0.39 1.81* 10.22* 0.96* 2.55* 20.43* 42.96 13.89 39.71 16.48* 22.57* 0.81* 10.77* 0.53*
s.d. 4.52 1.72 4.57 3.28 0.51 0.10 0.91 3.93 0.24 0.36 2.58 8.07 4.59 6.02 6.13 4.12 0.48 3.14 0.15
PS CTR 6.22 2.16 26.07 23.76 3.69 1.10 2.27 13.12 2.50 5.74 7.52 32.40 24.94 38.00 20.12 16.73 1.25 6.03 1.90
s.d. 1.88 1.96 9.75 6.53 1.62 1.07 0.99 7.67 1.20 1.69 3.71 9.19 7.87 11.64 10.49 4.72 0.68 3.59 1.64
PS AA 13.48* 4.69* 21.00 25.00 2.00* 0.48* 0.29* 14.87 0.41* 1.82* 6.07 34.38 29.80 26.37* 17.81 8.56* 2.12* 47.07* 2.86
s.d. 1.77 1.71 4.77 4.62 0.61 0.21 0.16 4.00 0.23 0.63 1.75 3.20 3.57 4.01 4.27 0.98 0.70 29.02 1.92
PS EPA 6.17 1.38 14.67* 18.78 1.76* 0.35* 1.34 6.96* 16.53* 23.17* 2.48* 27.92 19.97 48.44 10.06* 38.38* 0.29* 0.48* 2.18
s.d. 1.30 0.65 4.30 3.79 0.55 0.11 1.12 4.17 0.34 7.45 0.59 13.86 4.06 13.24 4.27 12.21 0.14 0.27 0.83
PS DHA 11.48* 2.44 28.32 10.43* 1.60* 0.32* 0.42* 9.99 1.23* 2.41* 30.84* 36.77 12.26* 45.48 10.63 34.49* 0.32* 9.65 0.33*
s.d. 3.46 1.48 13.14 1.56 0.29 0.06 0.13 2.22 0.40 0.83 8.78 17.15 3.15 11.23 3.27 8.40 0.09 3.81 0.05
PC CTR 23.82 3.13 13.90 35.51 6.45 1.29 1.43 8.17 1.20 1.88 2.29 37.73 38.64 22.62 16.04 6.58 2.50 7.50 3.86
s.d. 3.82 1.19 2.11 3.70 0.84 0.17 0.37 2.43 0.44 0.64 0.72 3.25 3.55 2.82 2.26 1.15 0.47 3.56 1.43
PC AA 27.29* 3.84 11.20* 21.03* 2.66* 0.53* 1.02* 27.61* 0.10* 1.45* 1.33* 38.50 24.87* 34.80* 31.29* 3.51* 8.89* 277.85* 18.21*
s.d. 1.51 0.42 0.69 1.98 0.18 0.04 0.13 3.19 0.01 0.23 0.28 1.43 2.03 3.27 3.13 0.15 0.56 34.12 2.17
PC EPA 25.10 1.63* 9.05* 20.73* 4.33* 0.87* 0.83* 3.62* 15.71* 14.26* 1.36 34.14 22.36* 40.96* 8.77* 32.17* 0.28* 0.24* 3.42
s.d. 3.84 0.25 1.94 1.79 0.66 0.13 0.42 0.53 2.09 5.43 0.93 4.74 1.92 6.92 0.36 6.75 0.05 0.04 1.29
PC DHA 23.54 2.89 13.68 16.85* 3.07* 0.61* 0.96* 7.16 1.78* 1.80 23.90* 37.41 20.77* 39.77* 11.80* 27.96* 0.43* 4.12* 0.33*
s.d. 2.72 0.88 1.65 3.35 0.37 0.08 0.25 0.98 0.45 0.66 4.15 4.53 1.62 3.56 0.42 3.75 0.08 0.54 0.09
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6Table 2 Phospholipids fatty acid composition of PUFA-treated MDA-MB-231 (Continued)
SM CTR 20.03 2.74 14.34 21.96 3.21 0.80 1.11 8.09 1.17 3.16 6.05 33.78 22.98 24.11 12.93 11.18 1.34 11.07 1.73
s.d. 9.10 1.62 8.11 7.61 1.60 0.73 1.09 3.47 1.17 2.87 3.57 16.17 9.73 6.62 4.26 4.31 0.45 7.33 0.83
SM AA 18.75 2.94 10.40 20.80 2.24 0.45 0.53* 12.30* 0.75 0.63* 6.68 33.32 23.22 22.58 14.80 8.45* 1.76* 30.33* 1.86
s.d. 5.27 1.67 1.00 4.33 0.93 0.19 0.15 0.96 0.54 0.34 0.94 14.58 4.99 1.84 1.45 0.29 0.23 10.50 0.26
SM EPA 12.67* 1.99 6.43* 24.50 2.07* 0.41 0.38* 7.85 4.38* 6.28* 2.93* 19.11* 24.70 26.51 13.17 16.24 0.90 1.78* 3.47
s.d. 3.19 0.78 0.67 2.85 0.71 0.14 0.06 2.91 1.67 2.13 1.48 3.51 7.82 6.22 5.26 7.02 0.45 0.83 2.00
SM DHA 19.07 5.01* 14.14 13.62* 2.89 0.58 1.72 5.60* 1.20 1.24* 8.35 33.21 19.47 25.69 10.21* 15.48 0.79* 5.76* 0.70*
s.d. 6.89 0.79 3.32 1.01 0.42 0.08 0.73 1.88 0.53 0.23 2.52 9.19 2.32 7.32 1.37 7.31 0.37 3.21 0.37
Values are expressed as percentage of total fatty acids (means bold numbers, SD plain numbers).
CTR n = 15, Treated n=6; * P < 0.01
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6Table 3 Phospholipids fatty acid composition of PUFA-treated MCF7
C16:0 C16:1 C18:0 C18:1 C18:2 C18:3 C20:3 C20:4 C20:5 C22:5 C22:6 SFA MUFA PUFA n-6 PUFA n-3 PUFA Omega-6/Omega-3 AA/EPA AA/DHA
PE CTR 7.76 4.23 22.01 23.50 3.46 0.69 1.70 24.93 5.28 0.72 5.71 29.77 27.73 42.50 30.09 12.41 2.47 4.75 4.58
s.d. 1.18 1.91 1.92 3.14 0.69 0.14 0.28 3.13 0.69 0.56 1.37 1.86 3.83 3.88 2.66 1.96 0.37 0.50 1.04
PE AA 8.24 1.52* 33.44* 8.05* 1.38* 0.28* 0.49* 42.32* 0.70* 1.03 2.56* 41.68* 9.57* 48.75* 44.19* 4.57* 9.97* 76.64* 17.85*
s.d. 1.62 0.95 1.22 1.04 0.20 0.04 0.25 2.15 0.47 0.39 0.81 1.44 1.57 2.19 1.94 0.86 1.80 30.68 5.10
PE EPA 9.52 2.19* 27.35* 8.58* 1.50* 0.30* 0.53* 7.37* 33.91* 7.68* 1.07* 36.87* 10.77* 52.36* 9.40* 42.96* 0.23* 0.22* 5.42
s.d. 2.55 1.22 2.29 2.80 0.52 0.10 0.26 1.10 4.88 2.26 0.50 1.58 4.00 5.13 1.76 6.77 0.08 0.06 0.45
PE DHA 9.26 1.36* 25.39 6.97* 2.08* 0.42* 1.03 6.62* 9.45* 0.52 36.92* 34.65* 8.33* 57.02* 9.73* 47.30* 0.21* 0.71* 0.19*
s.d. 2.80 1.10 4.61 2.50 1.24 0.25 1.00 1.43 2.19 0.33 7.43 4.38 2.66 6.35 1.95 6.27 0.05 0.13 0.08
PI CTR 10.84 2.51 31.95 18.13 3.43 0.69 5.50 14.10 2.22 1.64 8.99 42.79 20.65 36.56 23.02 13.54 1.80 8.04 1.84
s.d. 5.40 2.32 5.42 6.55 1.29 0.26 1.53 3.89 1.65 1.00 3.07 5.35 7.91 7.50 4.66 3.77 0.47 4.32 1.20
PI AA 8.22 1.04* 35.22* 6.79* 1.45* 0.29* 1.01* 40.65* 0.96* 1.52 2.83* 43.44 7.83* 48.73* 43.12* 5.61* 8.34* 69.09* 23.36*
s.d. 1.78 0.73 2.36 3.69 0.34 0.07 0.13 3.84 0.80 1.41 1.77 2.35 4.03 2.81 3.70 1.65 2.63 49.53 17.92
PI EPA 8.81 1.66 33.04 6.85* 2.18* 0.44* 1.48* 10.41* 24.41* 8.60* 2.13* 41.84 8.51* 49.65* 14.07* 35.57* 0.40* 0.44* 4.76
s.d. 1.58 1.04 1.55 2.31 0.79 0.16 0.61 0.92 4.29 1.69 2.18 1.73 2.04 2.96 1.61 3.59 0.08 0.10 3.02
PI DHA 9.06 1.23* 24.60* 13.54 4.52 0.91 3.11 7.63* 7.71* 0.87* 26.82* 33.66* 14.77* 51.57* 15.26* 36.31* 0.43* 1.16* 0.31*
s.d. 3.81 0.91 5.96 5.74 2.54 0.51 3.09 1.55 3.67 0.76 6.04 6.91 5.63 7.46 5.64 5.29 0.19 0.48 0.17
PS CTR 10.79 3.53 24.95 27.92 4.30 0.86 4.21 11.93 3.18 2.19 6.14 35.75 31.45 32.81 20.43 12.37 1.83 5.17 2.49
s.d. 3.01 2.22 8.41 7.49 1.77 0.35 1.57 5.37 1.91 2.00 3.36 8.35 8.32 8.96 7.21 4.27 0.84 4.46 1.57
PS AA 11.97 1.92 29.81 12.97* 2.24* 0.45* 1.07* 33.50* 1.21* 1.69 3.18* 41.78* 14.89* 43.33* 36.80* 6.53* 6.49* 38.97* 12.22*
s.d. 4.28 2.83 7.69 4.92 1.33 0.27 0.43 11.48 0.63 2.12 1.47 5.84 7.35 9.32 10.79 2.15 3.45 31.62 6.48
PS EPA 16.78* 1.07* 20.16 7.31* 1.27* 0.25* 1.36* 7.62 33.04* 8.11* 3.05 36.93 8.37* 54.70* 10.25* 44.45* 0.22* 0.22* 4.62
s.d. 3.53 0.69 11.14 3.65 0.53 0.11 0.66 3.42 12.94 3.14 3.04 11.06 3.52 14.23 3.84 10.79 0.06 0.06 4.12
PS DHA 9.83 1.78* 24.73 13.57* 3.40 0.68 1.75* 6.67* 5.00 1.55 31.06* 34.56 15.35* 50.10* 11.82* 38.28* 0.32* 1.85* 0.22*
s.d. 3.89 1.47 6.84 3.83 1.70 0.34 1.30 3.26 2.94 0.59 2.17 6.22 3.88 4.33 5.70 4.53 0.18 1.50 0.12
PC CTR 28.42 13.13 6.51 36.22 4.19 0.84 1.52 5.18 1.18 0.59 2.23 34.93 49.35 15.73 10.89 4.83 2.61 5.70 3.91
s.d. 4.83 5.72 1.57 4.15 0.85 0.17 0.66 1.79 0.62 0.92 2.01 3.83 4.82 5.01 2.61 2.95 0.85 3.65 3.51
PC AA 28.28 4.97* 10.89* 16.67* 1.92* 0.38* 0.58* 34.61* 0.19* 0.29 1.21* 39.16* 21.65* 39.19* 37.11* 2.08* 18.12* 222.12* 30.38*
s.d. 2.59 1.87 2.23 0.69 0.05 0.01 0.05 1.68 0.10 0.07 0.33 0.63 1.61 1.91 1.61 0.33 2.44 100.56 8.64
PC EPA 36.02 8.05 5.93 19.61* 2.64* 0.53* 0.56* 3.72 20.12* 1.75 1.07 41.95* 27.66* 35.69* 6.92* 23.48* 0.34* 0.21* 4.37
s.d. 4.52 3.18 0.62 4.19 0.29 0.06 0.34 1.29 8.27 1.39 0.63 0.91 6.34 0.53 1.68 9.30 0.17 0.10 2.54
PC DHA 29.09 3.68* 9.94* 14.94* 3.37* 0.67* 1.42 5.14 10.01* 0.39 21.34* 39.03* 18.62* 42.35* 9.93 32.42* 0.32* 0.51* 0.26*
s.d. 5.46 2.60 1.71 3.86 0.46 0.09 0.39 0.99 1.36 0.20 5.63 4.11 5.19 6.44 1.47 6.01 0.07 0.06 0.08
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6Table 3 Phospholipids fatty acid composition of PUFA-treated MCF7 (Continued)
SM CTR 29.95 3.73 15.64 18.03 3.22 0.64 1.86 13.35 4.32 3.66 5.59 45.60 21.76 32.64 18.43 14.22 1.60 4.45 6.27
s.d. 10.86 3.23 5.22 12.01 2.59 0.52 1.75 7.22 2.64 4.77 6.24 14.67 13.34 11.00 7.83 7.61 1.01 4.12 7.52
SM AA 17.58* 2.89 11.48* 20.36 2.56 0.51 2.16 17.74 4.16 6.86 5.97 29.06* 23.25 47.70* 22.46 15.86 1.50 6.56 3.41
s.d. 3.70 1.81 2.48 14.89 1.24 0.25 1.20 4.82 2.46 2.41 2.77 5.41 15.15 13.59 5.90 5.92 0.48 5.17 1.33
SM EPA 22.22* 13.52* 10.43* 5.06* 1.62* 0.32* 5.71 10.28 7.24 7.54* 16.06 32.65* 18.57 48.78* 17.62 31.16* 0.59* 1.49* 0.74*
s.d. 2.85 2.24 1.59 0.20 0.65 0.13 3.16 3.56 2.52 1.84 8.51 3.98 2.43 5.54 4.86 6.18 0.22 0.52 0.37
SM DHA 27.05 5.19 11.33* 23.02 3.99 0.80 1.30 9.78 2.65* 4.38 10.53 38.38 28.21 33.41 15.06* 18.35 0.94 4.00 1.05*
s.d. 10.74 4.69 2.93 20.63 1.93 0.39 0.89 5.93 0.60 3.81 8.19 12.47 18.30 15.33 6.22 11.75 0.41 2.60 0.47
Values are expressed as percentage of total fatty acids (means bold numbers, SD plain numbers).
CTR n=5, Treated n=6; * P < 0.01
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Figure 5 Content of AA (C20:4), EPA (C20:5), DPA (20:6), DHA (C22:6), SFA and MUFA in PLs of MDA-MB-231 cells treated with
LCPUFAs. MDA-MB-231 cells were treated with AA, EPA, and DHA. Purification of single PL moieties was achieved with an HPLC-ELSD system.
PL fatty acids were determined as methyl esters by gas chromatography (GC). Data are reported as percentage of total fatty acids. Controls are
not exposed to any exogenous fatty acids. * p < 0.01; n = 3.
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Figure 6 Content of AA (C20:4), EPA (C20:5), DPA (20:6), DHA (C22:6), SFA and MUFA in PLs of MCF7 cells treated with LCPUFAs. MCF7
cells were treated with AA, EPA, and DHA. Purification of single PL moieties was achieved with an HPLC-ELSD system. PL fatty acids were
determined as methyl esters by gas chromatography (GC). Data are reported as percentage of total fatty acids. Controls are not exposed to any
exogenous fatty acids. * p < 0.01; n = 3.
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Page 13 of 16Fas and TNFR1 induce the activation of a set of cysteine
proteases called caspases. Studies designed to elucidate
the mechanism(s) by which Fas and TNFR1 stimulation
lead to caspase activation are underway. In the case of
Fas, receptor aggregation by the Fas ligand induces the
formation of a death-inducing signalling complex (DISC)
of proteins comprising Fas itself, the adaptor protein
FADD and the inactive zymogen form of caspase-8.
Shortly after formation of the DISC, procaspase-8 is
cleaved and the active protease is released. Once acti-
vated, caspase-8 is thought to activate other downstream
caspases by proteolytic cleavage of their zymogen forms,
thus amplifying the caspase signal [35]. Our results
demonstrate the activation of caspase-8 in response to
incubation with n-3 PUFAs by a reduction of the levels
of its zymogen form in both cell lines. In many cells,
over-expression of either Bcl2 or Bcl-xl inhibits apopto-
sis, affecting the release of cyt-c and apoptosis-inducing
factor (AIF) from the mitochondrial intramembrane
space to the cytosol. Once released, AIF is translocated
to the nucleus where it is capable of inducing nuclear
chromatin condensation and large-scale DNA fragmenta-
tion that mediates a caspase-independent mitochondrial
apoptotic pathway [36]. Cyt-c, together with dATP, binds
to apoptotic proteinase activating factor-1 (Apaf-1) and
this complex promotes procaspase-9 autoactivation. The
active forms of caspase-8 and caspase-9 might activate
the downstream effectors caspase-3, -6 and -7, resulting
in the cleavage of crucial cellular proteins and apoptosis.
We have observed a significant difference in the amount
of Bcl2 present in the DHA-treated MDA-MB-231 cells
and EPA-treated MCF7 cells compared to the control
group. The absence of Bcl2 when compared to the con-
t r o li ss u g g e s t i v et h a tt h ec e l lm i g h tb em o r el i k e l yt o
proceed to apoptosis.
EGFR is an interesting target for tumour therapy,
because it is over-expressed in many human tumours
such as lung and breast cancers [37]. MDA-MB-231
cells express high levels of EGFR and are a good model
to study EGFR modulation by n-3 PUFAs. This receptor
is a member of the ErbB receptor tyrosine kinase family,
which consists of EGFR (or HER1 or ErbB1), HER2/
ErbB2, HER3/ErbB3 and HER4/ErbB. Ligand binding to
EGFR induces its dimerization with another EGFR or
with other members of the ErbB family, and activates
tyrosine kinase residues on the intracellular domains of
the protein through autophosphorylation. EGFR recruits
downstream signalling proteins, triggering signal cas-
cades along a number of pathways that eventually lead
to cell growth, migration and apoptosis resistance
[38,39]. We found that the phosphorylated EGFR levels
are reduced after treatment with n-3 PUFAs (EPA or
DHA) in MDA-MB-231 cells, whereas the EGFR level
was decreased only after incubation with DHA.
The entire mechanism by which n-3 PUFAs exert
their beneficial effects is not fully understood. We have
hypothesized that the induction of apoptosis, the reduc-
tion of cell proliferation and the inhibition of EGFR
activity by these fatty acids might be the consequences
of cell membrane alterations induced by FA. Our data
indicate that EPA and DHA are incorporated in breast
cancer membrane. In particular the EPA treatment
determines an increase of EPA and DPA content, and a
reduction of SFA, MUFA and n-6 PUFA concentration
in both cell lines. This suggests an incorporation of EPA
which is further metabolised. In fact, EPA is converted
to 22:5 n-3 (DPA) by elongase (Elovl)-5 and then by
Elovl-2 to 24:5, n-3. The next step requires desaturation
of 24:5 by Δ6 desaturase to produce 24:6, n-3. This pro-
duct is translocated from the endoplasmic reticulum to
the peroxisome, where the b oxidation pathway involves
acyl chain shortening of C2 to produce DHA [40].
Also DHA incubation determines an increase of EPA, of
DHA, and in general of the unsaturation degree in both
cell lines. We have also observed that PUFAs are incorpo-
rated into the breast cancer membrane with different spe-
cificity for each PL moiety. The enrichment is significant,
especially in PE, PI and PC. The transbilayer distribution
of lipids across biological membranes is asymmetric. The
choline-containing lipids PC and SM are enriched primar-
ily on the external leaflet of the plasma membrane or
the topologically equivalent luminal leaflet of internal
organelles. In contrast, the amine-containing glyceropho-
spholipids PE and PS are located preferentially on the
cytoplasmic leaflet. Other minor PLs, such as phosphatidic
acid (PA), PI and phosphatidylinositol-4,5-bisphosphate
(PIP2) are also enriched on the cytofacial side of the mem-
brane. Specific alterations of the molecular composition of
the plasma membrane occur during apoptosis. Hence,
cells undergoing apoptosis express signals, including lipids,
proteins and modified sugar moieties that facilitate recog-
nition and ingestion by macrophages. Loss of transmem-
brane PL asymmetry, with consequent exposure of PS in
the external monolayer, occurs in both normal and patho-
logic conditions. PS externalization is induced early in the
process of apoptosis. On the basis of our findings, the data
suggest that the incorporation of n-3 PUFAs is mainly
into cytofacial leaflet PLs, altering the membrane environ-
ment to impact on the activation of cell signalling. More-
over, a significant decrease of SM was evident in cells
treated with DHA.
Once lipid asymmetry has been established, it is main-
tained by a combination of slow transbilayer diffusion,
protein-lipid interactions andp r o t e i n - m e d i a t e dt r a n s -
port. The most significant contributors to the mainte-
nance and dissipation of transbilayer lipid asymmetry are
proteins that catalyse the movement of lipids across the
membrane. Two classes of transport activities have been
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transport of lipids. The best characterized activity is flip-
pase, which transports PS from the outer monolayer to
the cytoplasmic surface of the plasma membrane and
requires ATP and Mg
2+ but its activity is inhibited by
Ca
2+. A second ATP-dependent activity, catalysed by flip-
pases, transports lipids in the opposite direction. The
third class of lipid transporter consists of the Ca
2+-acti-
vated scramblases that catalyse the PS externalization
[41,42]. Growing evidence indicates that excessive con-
centrations of FA affect cell functions by altering the
activity of various ion transporters and channels, includ-
ing Ca
2+.Z h a n get al. have found that PUFAs, but not
monounsaturated or saturated FAs, cause [Ca
2+]i mobili-
zation in NT2 human tetracarcinoma cells by causing
release of this proton from mitochondria [43]. Further-
more, Djemli-Shipkolye et al. showed that FA modifica-
tions in membranes could be correlated with the
variations observed in the activity of ATPase, for instance
of Mg-ATPase [44]. This effect could influence the flip-
pase and scramblase activities, and thus the transbilayer
lipid asymmetry.
Moreover PUFA incorporation induces an alteration
of SFA, MUFA and PUFA content in membrane phos-
pholipids; these data suggest a metabolic rearrangement
in cells in order to try to balance the ratio between satu-
rated and unsaturated fatty acids.
In addition membranes constitute a meeting point for
lipids and proteins. Thousands of cellular proteins inter-
act with membranes in different ways, for example inte-
gral (transmembrane, as EGFR) proteins are embedded
in the lipid bilayer and their activity is sensitive to
changes in the lipid environment. Recently, multiple stu-
dies demonstrated very rapid ERa actions at level of the
plasma membrane [45]. O’Malley and collaborators have
demonstrated that ERa on the membrane initially acti-
vates cytoplasmic kinases, which in turn phosphorylate
and activate coactivators proteins in the cytoplasm.
These coactivators then travel to the nucleus and modu-
late ERa-mediated transcriptional events [46].
Then n-3 PUFAs, modifying the unsaturated degree,
the permeability, the flip-flop process and the fluidity of
the plasma membrane, might alter the activity of these
proteins. This hypothesis will be investigated in our
laboratory.
Conclusions
We suggest that n-3 PUFAs induce modifications of
membrane structure and function of breast cancer cells,
thereby increasing the degree of unsaturation. These
changes of plasma membrane might modify the mem-
brane architecture and signal transduction causing a
reduction of cell proliferation and apoptosis induction.
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